Eli Lilly’s “contrarian” strategy widens its lead as rivals focus on replacing expiring drug revenue

Eli Lilly is increasingly viewed by investors and industry trackers as a company that is not merely benefiting from the current obesity and diabetes drug boom, but also gaining ground faster than its closest rivals as they prepare for the long-term reality of patent expirations. In a recent commentary, PharmaVoice framed the situation as an unusual “distance” between Lilly and the rest of large pharma, arguing that many companies are scrambling to refill pipelines while Lilly continues to compound growth.

The article pointed to a projection from Evaluate, based on an analysis cited in the same piece, that could put Lilly’s annual sales at about $137 billion by 2032. That would be roughly 60% more than AbbVie, the article said was the closest competitor in that scenario. While such forecasts depend on future trial outcomes and continued demand, the comparison underscored why the market has treated Lilly’s revenue stream as more durable than the industry average.

Lilly’s standing in annual rankings was also highlighted. The piece said Lilly climbed from ninth to first place this year in the Pharma 50 rankings, a list compiled by Drug Discovery and Development. It placed Lilly just ahead of Merck & Co., using revenue as the yardstick in that ranking framework. In the article’s telling, the ranking strength reflects both present sales and the company’s ability to keep expanding its portfolio rather than waiting for a pipeline reset.

Much of the attention remains on Lilly’s weight-loss and diabetes medicines, including Mounjaro and Zepbound. The PharmaVoice piece said the next phase of that franchise includes a daily pill option called Foundayo, describing it as an additional formulation that could broaden access beyond injections. The article further said sales projections also factor in investigational weight-loss options, including retatrutide, whose clinical trial data were characterized in the commentary as potentially exceeding approved drugs on weight loss.

The piece also cited another Lilly candidate, eloralintide, describing its target as the pancreatic hormone amylin. That matters because amylin is part of the body’s metabolic indicating network, and the article suggested the scientific approach could address tolerability issues that sometimes limit patient persistence with current weight-loss medications. The commentary did not provide detailed safety numbers in the excerpt, but it tied the drug’s mechanism to the broader competitive race to improve the overall GLP-1 experience.

Competition in GLP-1 and obesity pharmacology has been intense, with Novo Nordisk holding early leadership. The article said Lilly overtook Novo last year, and it attributed at least part of that reversal to Lilly’s pace of product development and its ability to keep its commercial lineup ahead of looming competitive changes. It also included a quote from Dan Chancellor, vice president of thought leadership at Evaluate’s parent company Norstella, who said he could not recall a time when there was such a large gap between the No. 1 pharma company and the pack.

Chancellor’s remarks in the piece emphasized relative growth rates, saying Lilly was the only company in the top 10 pharmas that was growing above average market rates, while others were below average. In other words, the argument is not only that Lilly has large sales today, but that its growth trajectory is stronger than peers as the obesity drug category expands and evolves.

Still, some key details are absent from what was published in the excerpt. The article does not break down how much of the projected 2032 revenue depends on regulatory outcomes for retatrutide and other candidates, nor does it quantify safety, pricing, or patient retention assumptions. It also does not specify how Foundayo’s performance compares with competitors in oral obesity drugs beyond the general framing of an emerging daily-pill option.